硼替佐米治疗多发性骨髓瘤致严重带状疱疹一例
被引量:1
摘要
患者男,73岁,汉族,因咳嗽、活动后气短4个月就诊于外院,行血常规提示全血细胞减少,胸部CT提示右肺尖后26mm×36mm软组织影,邻近肋骨可见囊状骨破坏。骨髓穿刺提示异常浆细胞0.52,诊断多发性骨髓瘤(MM)。
出处
《白血病.淋巴瘤》
CAS
2012年第8期509-510,共2页
Journal of Leukemia & Lymphoma
参考文献8
-
1赵娜(综述),杨俊杰(审校).蛋白酶体抑制剂硼替佐米治疗多发性骨髓瘤的分子机制[J].白血病.淋巴瘤,2011,20(11):698-700. 被引量:5
-
2陈飞,王玉娟,张克俭,左学兰,詹竹英.硼替佐米联合地塞米松及沙利度胺治疗多发性骨髓瘤临床观察[J].临床血液学杂志,2011,24(2):176-177. 被引量:17
-
3钟玉萍,陈世伦.硼替佐米治疗复发难治性多发性骨髓瘤43例[J].白血病.淋巴瘤,2009,18(9):538-540. 被引量:6
-
4Jones JO, Arvin AM. Inhibition of the NF- K B pathway by varicella zoster virus in vitro and in human epidermal ceils in vivo. J Virol, 2006, 80:5113-5124.
-
5Berges C, Haberstock H, Fuchs D, et al. Proteasome inhibition suppresses essential immune functions of human CD ~ T cells. Immunology, 2008, 124: 234-246.
-
6Heider U,V'Rademacher J, Kaiser M, et al. Decrease in CD: T-cell counts in patients with multiple myeloma treated with bortezomib. Clin Lymphoma Myeloma Leuk, 2010, 10: 134-137.
-
7Seok J, Kim KK, Young RD, et al. Low-dose acyciovir is effective for prevention of herpes zoster in myeloma patients treated withbortezomib: a report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study. Leukemia, 2010, 24: 1350-1356.
-
8Aoki T, Nishiyama T, Imahashi N, et al. Efficacy of continuous,daily, oral,ultra-low-dose 200 mg acyclovir to prevent herpes zoster events among bortezomib-treated patients: a report from retrospective study. Jpn J Clin Oncol, 2011, 41: 876-881.
二级参考文献50
-
1邱录贵.多发性骨髓瘤的发病与国人特点[J].中国实用内科杂志:临床前沿版,2006,26(6):886-888. 被引量:52
-
2Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. Blood, 2004, 103: 20-32.
-
3Bataille R. Harousseau JL. Multiple myeloma. The New England Journal of Medicine, 1997, 336: 1657-1664.
-
4The UK Myeloma Forum Guidelines Working Group.Diagnosis and management of multiple myeloma. Bri J Haematol, 2001, 115: 522-540.
-
5Blad e, J, Samson D, Reeee D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT.European Group for Blood and Marrow Transplant. Br J Haematol. 1998. 102:1115-1123.
-
6Popat R, Oakervee H, Williams C, et al. Bortezomid,low-dose intravenous melphalan,and dexamethasone for patients with relapsed muhiple myeloma. Br J Haematol, 2009, 144: 887-894.
-
7Podar K, Tai YT, Hideshima T, et al. Emerging therapies for multiple myeloma. Expert Opin Emerg Dnlgs, 2009, 14: 99-127.
-
8Berenson JR, Yang HH, Vescio RA, et al. Safety and efficacy of bortezomid and melphalan combination in patients with relapsed or refractory multiple myeloma:updated results of a phase 1/2 study after longer follow-up. Ann Hematol, 2008, 87:623-631.
-
9BladeJ, Sonneveld P, San Miguel JF, et al. Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory. muhiple myeloma: efficacy and safety in patients with renal function impairment. Clin Lymphoma Myeloma, 2008, 8: 352-355.
-
10RICHARDSON P G,BARLOGIE B,BERENSON J,et al.A phase 2 study of bortezomib in relapsed/refractory myeloma[J].N Engl J Med,2003,348:2609-2617.
共引文献25
-
1高静.硼替佐米治疗多发性骨髓瘤的临床观察及护理[J].医学信息(医学与计算机应用),2016,29(36):198-198. 被引量:1
-
2王婧,周新.VTD方案对多发性骨髓瘤患者凝血功能的影响[J].求医问药(下半月),2013(4):45-45. 被引量:2
-
3陈世伦(综述).多发性骨髓瘤的靶位治疗[J].国际输血及血液学杂志,2010(1):14-17.
-
4傅国英.硼替佐米联合地塞米松治疗多发性骨髓瘤患者的护理[J].现代实用医学,2012,24(1):105-106. 被引量:1
-
5李斯丹,徐燕,安刚,赵耀中,邹德慧,邱录贵,王亚非.双膦酸盐类药物治疗骨髓瘤骨病的临床研究[J].白血病.淋巴瘤,2012,21(7):397-400. 被引量:3
-
6苏爱玲,张磊,张秀群,徐燕丽.硼替佐米联合地塞米松改良方案治疗多发性骨髓瘤的临床观察[J].白血病.淋巴瘤,2013,22(4):240-242. 被引量:2
-
7邱会玲.硼替佐米治疗多发性骨髓瘤的临床观察及护理[J].临床医药实践,2013,22(6):463-464. 被引量:4
-
8韦金华.多发性骨髓瘤诊治研究进展[J].中外医学研究,2014,12(3):161-162. 被引量:8
-
9胡炜,王嵬,高振宇.硼替佐米体外对前列腺癌细胞迁移和侵袭的影响及其机制[J].肿瘤研究与临床,2014,26(2):98-101. 被引量:4
-
10李学亮,袁明智.不同硼替佐米剂量的PAD化疗方案治疗多发性骨髓瘤后患者的临床疗效和不良反应的评估[J].中国现代医学杂志,2014,24(30):84-87. 被引量:3
同被引文献7
-
1马哲河.恶性肿瘤放化疗并发带状疱疹21例临床分析[J].实用临床医学(江西),2002(5):92-92. 被引量:3
-
2张之南,沈悌.血液病诊断与疗效标准[M].3版.北京:科学出版社,2007:116-121.
-
3Natsume A, Niwa R, Satoh M. Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC[J]. Drug Des Devel Ther, 2009, 21: 7-16.
-
4Takaqi K, Kawai Y, Yamanchi T, et al. Synergistic effects of combination with fludarabine and carboplatin depend on fludarabine- mediated inhibition of enhanced nucleotide excision repair in leukemia [J]. Int J Hematol, 2011, 94: 378-389.
-
5张明智,张旭东,臧卫平.美罗华联合化疗治疗B细胞非霍奇金淋巴瘤25例[J].肿瘤基础与临床,2008,21(2):129-130. 被引量:12
-
6崔利,谷潇,时莎,王斯.蛋白酶体抑制剂在癌症治疗中的作用[J].医学综述,2010,16(9):1319-1321. 被引量:3
-
7苏静,慕俐君,孙健.R—CHOP方案治疗复发、难治弥漫大B细胞淋巴瘤的临床研究[J].白血病.淋巴瘤,2012,21(10):601-603. 被引量:6
-
1孙超,王婧,毛静珏,郭宏锋,周新.硼替佐米对多发性骨髓瘤患者CD4+T淋巴细胞的影响[J].中华临床医师杂志(电子版),2012,6(23):7857-7858. 被引量:1
-
2高娟.肿瘤患者术后放疗和化疗期间并发带状疱疹25例临床分析[J].临床皮肤科杂志,2005,34(12):860-860. 被引量:2
-
3丛林,常冬青,苏有明,杨蓉娅.乳腺癌皮肤转移误诊为带状疱疹1例分析[J].中国误诊学杂志,2008,8(4):763-763. 被引量:3
-
4石英,聂发传,王素匣.芬太尼透皮贴剂用于30例难治性PHN的疗效及不良反应[J].重庆医学,2013,42(33):4026-4027.
-
5滕熔.多发性骨髓瘤83例临床分析[J].临床误诊误治,2003,16(1):39-40. 被引量:2
-
6秦宗永,张美玲,王军,车现斌.多发性骨髓瘤16例误诊分析[J].临床误诊误治,2003,16(1):40-41. 被引量:3
-
7房芳.天睛依泰治疗多发性骨髓瘤13例护理体会[J].齐鲁护理杂志,2005,11(10):1405-1406.
-
8鹿军,王青蓝,任刚.多发性骨髓瘤26例误诊分析[J].哈尔滨医药,2007,27(1):41-42. 被引量:1
-
9杨新宏,杨晓峰,李海洋,武英伟.18例多发性骨髓瘤的实验室诊断分析[J].中国实验诊断学,2013,17(6):1099-1100. 被引量:4
-
10徐建荣,丁以星,夏福林.白细胞介素-2治疗带状疱疹的临床效果观察[J].中国基层医药,2016,23(24):3757-3759. 被引量:2